Abstract:Introduction: Active tuberculosis (TB) is an uncommon but life-threatening complication of haematopoietic stem cell transplantation (HSCT). HSCT recipients are at significant high risk due to their immunocompromised state either because of delayed immune reconstitution or use of immunosuppressive medication for treatment of GVHD. Early recognition and prompt treatment are the key to good outcomes in this patient population. Methods: From January 2012 to December 2017, a nested case control study was carried out in our centre to examine active tuberculosis incidence and study relative risk factors. A total of 730 consecutive patients who underwent allogeneic HSCT were studied. Fourteen (1.92%) patients matched the established diagnostic criteria of active tuberculosis. Fifty-six allo-HSCT recipients were set as control. No significant difference was found between the two groups on age, gender, underlying disease, donor type and ATG given as well as conditioning intensity. Results: Twelve of the fourteen cases were pulmonary TB (85.7%), including four patients with miliary TB, while the other two were extrapulmonary TB (14.3%). The median time to onset of active TB was the 6.9 (range 1.5 to 32.5) months post-HSCT. The positive rate of T-SPOT in patients with TB is higher than those without TB, the difference was statistically significant.(HR =6.286, 95% CI,3.093-12.774; P =0.000). We also found Grades 2 to 4 aGVHD (HR = 3.975, 95% CI, 1.331-11.876; P =0.013), moderate-severe cGVHD (HR = 3.952, 95% CI, 1.113-14.027; P =0.033), Epstein Barr virus viremia (HR = 9.210, 95% CI, 1.204-70.452; P =0.032), the application of etanercept (HR=3.928, 95% CI,1.375-11.220; P =0.011), invasive fungal disease (HR = 3.909, 95% CI,1.351-11.316; P =0.012), relatively large dose of prednisone (HR=17.831, 95% CI, 2.330-136.476; P =0.006), and tacrolimus (HR=4.340, 95% CI, 4.340-4.340; P =0.009) were risk factors for active tuberculosis occurrence, but only the latter three remained significant after multivariate analysis. Each of the prognostic factors was assigned points based on their HR: invasive fungal disease (1 point); the use of FK 506(1 points); or presence of relatively large dose of prednisone (2 points).This total score stratified the cohort into 3 groups with very different risk of occurrence of TB: low risk group ( 0 to 1 point), the intermediate risk group ( 2 to3 points) , and the high risk group (4 points). The 5-year cumulative incidences of active TB were 0, 30.7%, and 77.8% for each risk groups (p=0.001). With a median follow-up of 15.9 (range 3.8-80.6) months for patients with TB and 43.1(range 3.4-80.3) months for control group without TB, the 3-year OS were 68.1% and 70.0%, respectively. Subjects with TB had significantly higher 3-year none relapse mortality than subjects without (24.76%±13.37% vs 5.66%±3.22%, P=0.0076). The causes of death in TB group were engraftment failure/multi-organ failure (n = 1), and respiratory failure(n = 3). Conclusions: Our study provides an excellent foundation for predicting of active TB occurrence in allo-HSCT recipients, and helps target high-risk patients for early diagnosis and timely management decision making. Figure. Figure. No relevant conflicts of interest to declare.

Changes in tuberculosis risk after transplantation in the setting of decreased community tuberculosis incidence: a national population-based study, 2008–2020

Tuberculosis in Kidney Transplant Recipients: A Nationwide Cohort in a Low Tuberculosis Incidence Country

Nationwide survey of infection prevention protocols in solid organ transplantation in South Korea

Risk factors and clinical outcomes of tuberculosis among kidney transplant recipients in high endemic country

Outcome and Risk Factors of Transplantation-Associated Active Tuberculosis in Allogeneic Haematopoietic Stem Cell Transplantation: A Nested Case Control Study

Incidence of Tuberculosis Among Immigrants in Korea Who Participated in a Latent Tuberculosis Infection Screening Program

Tuberculosis in kidney transplant candidates and recipients

Diagnostic delay and mortality of active tuberculosis in patients after kidney transplantation in a tertiary care hospital in China

Increased Risk of Incident Chronic Obstructive Pulmonary Disease and Related Hospitalizations in Tuberculosis Survivors: A Population-Based Matched Cohort Study

Safety and outcome of treatment of latent tuberculosis infection in liver transplant recipients

Frequency, Risk Factors, and Outcome of Active Tuberculosis Following Allogeneic Hematopoietic Stem Cell Transplantation.

Prognostic impact of preoperative respiratory colonization on early-onset pneumonia after lung transplantation

Tuberculosis survivors and the risk of cardiovascular disease: analysis using a nationwide survey in Korea

Changes in socioeconomic status and patient outcomes in kidney transplantation recipients in South Korea

Incidence of tuberculosis disease in individuals diagnosed with tuberculosis infection after screening: A population-based cohort study in South Korea

Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation

Incidence of systemic vasculitides after Mycobacterium tuberculosis infection: A population-based cohort study in Korea

Increased risk of genitourinary cancer in kidney transplant recipients: a large-scale national cohort study and its clinical implications

Identifying Predictors of Unfavorable Treatment Outcomes in Tuberculosis Patients

Risk of tuberculosis after achieving HIV virological suppression on antiretroviral therapy: a Danish nationwide prospective cohort study

Nationwide Implementation of Nonpharmaceutical Interventions During the Coronavirus Disease 2019 Pandemic Is Associated With Decreased Incidence of Pneumocystis jirovecii Pneumonia in Kidney Transplant Recipients